Lens culinaris agglutinin-reactive α-fetoprotein decline after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma predicts survival

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 232-238

  Huang, Chen ^a   Sheng, Shile ^a   Sun, Xiaoguang ^a   Liu, Jianju ^a   Huang, Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatocellular carcinoma; Lens culinaris agglutinin reactive fetoprotein; Radiologic imaging; Time resolved immunofluorometric assay; Transcatheter arterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; PHYTOHEMAGGLUTININ; LENTIL LECTIN; PLANT LECTIN;

ADOLESCENT; ADVANCED CANCER; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; LECTIN DUAL LABEL TIME RESOLVED IMMUNOFLUOROMETRIC ASSAY; LENTIL; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; ARTIFICIAL EMBOLISM; BLOOD; CHEMISTRY; FLUOROIMMUNOASSAY; LIVER TUMOR; MIDDLE AGED; PROCEDURES; PROGNOSIS; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUOROIMMUNOASSAY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84895762619     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.009     Document Type: Article

References (37)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. He J., Gu D., Wu X., et al. Major causes of death among men and women in China. N Engl J Med 2005, 353:1124-1134.
3. Llovet J.M., Real M.I., Montaña X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
4. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
5. WHO WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48 1979, WHO, Geneva, Switzerland.
6. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
7. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
8. Johnson P.J. Hepatocellular carcinoma: is current therapy really altering outcome?. Gut 2002, 51:459-462.
9. Johnson P.J. The role of serum alphafetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001, 5:145-159.
10. Leung T.W., Patt Y.Z., Lau W.Y., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5:1676-1681.
11. Lau W.Y., Leung T.W., Lai B.S., et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001, 233:236-241.
12. Barone R.M., Byfield J.E., Goldfarb P.B., Frankel S., Ginn C., Greer S. Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer 1982, 50:850-862.
13. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference-European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
14. Nomura F., Ohnishi K., Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer 1989, 64:1700-1707.
15. Lok A.S., Lai C.L. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989, 9:110-115.
16. The Cancer of the Liver Italian Program (CLIP) Investigators A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998, 28:751-755.
17. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
18. Lee Y.K., Kim S.U., Kim D.Y., et al. Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer Jan 3, 2013, 13(5). 10.1186/1471-2407-13-5.
19. Kao W.Y., Chiou Y.Y., Hung H.H., et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol 2012, 67:429-436.
20. Chan S.L., Mo F.K., Johnson P.J., et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009, 27:446-452.
21. Vora S.R., Zheng H., Stadler Z.K., Fuchs C.S., Zhu A.X. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009, 14:717-725.
22. Riaz A., Ryu R.K., Kulik L.M., et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009, 27:5734-5742.
23. Taketa K., Endo Y., Sekiya C., et al. A collaborative study for the evaluation of lectin-reactive alphafetoprotein in early detection of hepatocellular carcinoma. Cancer Res 1993, 53:5419-5423.
24. Li D., Mallory T., Satomura S. AFPL3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001, 313:15-19.
25. Sheng S.L., Wang Q., Huang G., Yu B., Qin W.X. Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays. J Clin Lab Anal 2009, 23:179-185.
26. Sheng S.L., Huang G., Yu B., Qin W.X. Clinical significance and prognostic value of serum Dickkopf-1 (DKK1) concentrations in patients with lung cancer. Clin Chem 2009, 55:1656-1664.
27. Fujiyama S., Tanaka M., Maeda S., Ashihara H., Hirata R., Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002, 62:S57-S63.
28. Hu K.Q., Kyulo N.L., Lim N., Elhazin B., Hillebrand D.J., Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004, 99:860-865.
29. Oka H., Saito A., Ito K., et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001, 16:1378-1383.
30. Yamashita F., Tanaka M., Satomura S., Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996, 111:996-1001.
31. Tada T., Kumada T., Toyoda H., et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005, 25:848-853.
32. Toyoda H., Kumada T., Osaki Y., Oka H., Kudo M. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 2007, 37(Suppl. 2):S166-S171.
33. Riaz A., Memon K., Miller F.H., et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011, 54:695-704.
34. Riaz A., Kulik L., Lewandowski R.J., et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009, 49:1185-1193.
35. Shimizu K., Katoh H., Yamashita F., et al. Comparison of carbohydrate structures of serum of α-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Clin Chim Acta 1996, 254:23-40.
36. Shimizu K., Taniichi T., Satomura S., Matsuura S., Taga H., Taketa K. Establishment of assay kits for the detection of microheterogeneities of α-fetoprotein using lectin-affinity electrophoresis. Clin Chim Acta 1993, 214:3-12.
37. Yamagata Y., Katoh H., Nakamura K., Tanaka T., Satomura S., Matsuura S. Determination of alpha-fetoprotein concentration based on liquid-phase binding assay using anion exchange chromatography and sulfated peptide introduced antibody. J Immunol Methods 1998, 212:161-168.